NAT2 and neoplasm: We sequenced the barcoded NAT2 amplicons from the normal tissues in two separate SMRT cells with 37 samples each, whereas the patient-matched tumor samples were sequenced in three additional SMRT cells with ~ 25 samples each, aiming for better tumor coverage.